Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival

Inhibition of the vascular endothelial growth factor (VEGF) pathway has failed to improve overall survival of patients with glioblastoma (GBM). We previously showed that angiopoietin-2 (Ang-2) overexpression compromised the benefit from anti-VEGF therapy in a preclinical GBM model. Here we investiga...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Proc Natl Acad Sci U S A
Glavni autori: Kloepper, Jonas, Riedemann, Lars, Amoozgar, Zohreh, Seano, Giorgio, Susek, Katharina, Yu, Veronica, Dalvie, Nisha, Amelung, Robin L., Datta, Meenal, Song, Jonathan W., Askoxylakis, Vasileios, Taylor, Jennie W., Lu-Emerson, Christine, Batista, Ana, Kirkpatrick, Nathaniel D., Jung, Keehoon, Snuderl, Matija, Muzikansky, Alona, Stubenrauch, Kay G., Krieter, Oliver, Wakimoto, Hiroaki, Xu, Lei, Munn, Lance L., Duda, Dan G., Fukumura, Dai, Batchelor, Tracy T., Jain, Rakesh K.
Format: Artigo
Jezik:Inglês
Izdano: National Academy of Sciences 2016
Teme:
Biological Sciences
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4843473/
https://ncbi.nlm.nih.gov/pubmed/27044098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1525360113
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items